Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conivaptan in pediatric hyponatremia
NCT01451411Phase 3Terminated
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hyponatremia comparing Conivaptan with Placebo (2 arms). Primary endpoint: Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum Sodium. Started Feb 2012; status: terminated.
02
Drugs
conivaptan
03
Conditions
hyponatremia
Beyond the preview
Go deeper on NCT01451411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451411.